Literature DB >> 23630657

Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint.

Liang Li1, Liang Wang, Zhaoyan Feng, Zhiquan Hu, Guoping Wang, Xianglin Yuan, He Wang, Daoyu Hu.   

Abstract

Prostate cancer is the most common cancer diagnosed in men and a leading cause of death. Accurate assessment is a prerequisite for optimal clinical management and therapy selection of prostate cancer. There are several parameters and nomograms to differentiate between patients with clinically insignificant disease and patients in need of treatment. Magnetic resonance imaging (MRI) is a technique which provides more detailed anatomical images due to high spatial resolution, superior contrast resolution, and multiplanar capability. State-of-the-art MRI techniques, such as diffusion weighted imaging (DWI), MR spectroscopic imaging (MRSI), dynamic contrast enhanced MRI (DCE-MRI), improve interpretation of prostate cancer imaging. In this article, we review the major role of MRI in the advanced management of prostate cancer to noninvasively improve tumor staging, biologic potential, treatment planning, therapy response, local recurrence, and to guide target biopsy for clinical suspected cancer with previous negative biopsy. Finally, future challenges and opportunities in prostate cancer management in the area of functional MRI are discussed as well.

Entities:  

Keywords:  Prostate cancer; magnetic resonance imaging; management; treatment

Year:  2013        PMID: 23630657      PMCID: PMC3636473          DOI: 10.3978/j.issn.2223-4292.2013.03.03

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  91 in total

1.  MRI-Compatible Pneumatic Robot for Transperineal Prostate Needle Placement.

Authors:  Gregory S Fischer; Iulian Iordachita; Csaba Csoma; Junichi Tokuda; Simon P Dimaio; Clare M Tempany; Nobuhiko Hata; Gabor Fichtinger
Journal:  IEEE ASME Trans Mechatron       Date:  2008-06-01       Impact factor: 5.303

Review 2.  Body MR imaging at 3.0 T: understanding the opportunities and challenges.

Authors:  Mara M Barth; Martin P Smith; Ivan Pedrosa; Robert E Lenkinski; Neil M Rofsky
Journal:  Radiographics       Date:  2007 Sep-Oct       Impact factor: 5.333

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  Concordance of preoperative prostate endorectal MRI with subsequent prostatectomy specimen in high-risk prostate cancer patients.

Authors:  Kenneth G Nepple; Henry M Rosevear; Alan H Stolpen; James A Brown; Richard D Williams
Journal:  Urol Oncol       Date:  2011-06-12       Impact factor: 3.498

5.  Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.

Authors:  Joan C Vilanova; Carles Barceló-Vidal; Josep Comet; Maria Boada; Joaquim Barceló; Joana Ferrer; Joan Albanell
Journal:  AJR Am J Roentgenol       Date:  2011-06       Impact factor: 3.959

6.  Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Alan W Partin
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

7.  When serial prostate biopsy is recommended: most cancers detected are clinically insignificant.

Authors:  Osama M Zaytoun; Andrew J Stephenson; Khaled Fareed; Ahmed El-Shafei; Tianming Gao; David Levy; J Stephen Jones
Journal:  BJU Int       Date:  2012-03-15       Impact factor: 5.588

8.  Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.

Authors:  T Y Chan; A W Partin; P C Walsh; J I Epstein
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

9.  Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.

Authors:  Liang Wang; Hedvig Hricak; Michael W Kattan; Lawrence H Schwartz; Steven C Eberhardt; Hui-Ni Chen; Peter T Scardino
Journal:  AJR Am J Roentgenol       Date:  2006-03       Impact factor: 3.959

10.  Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.

Authors:  Karl Mikael Kälkner; Thomas Wahlgren; Marianne Ryberg; Gabriella Cohn-Cedermark; Enrique Castellanos; Rolf Zimmerman; Josef Nilsson; Marie Lundell; Jack Fowler; Seymour Levitt; Magnus Hellström; Sten Nilsson
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

View more
  7 in total

1.  Development of high resolution 3D hyperpolarized carbon-13 MR molecular imaging techniques.

Authors:  Eugene Milshteyn; Cornelius von Morze; Galen D Reed; Hong Shang; Peter J Shin; Zihan Zhu; Hsin-Yu Chen; Robert Bok; Andrei Goga; John Kurhanewicz; Peder E Z Larson; Daniel B Vigneron
Journal:  Magn Reson Imaging       Date:  2017-01-07       Impact factor: 2.546

Review 2.  Current role of multiparametric magnetic resonance imaging for prostate cancer.

Authors:  Romaric Loffroy; Olivier Chevallier; Morgan Moulin; Sylvain Favelier; Pierre-Yves Genson; Pierre Pottecher; Gilles Crehange; Alexandre Cochet; Luc Cormier
Journal:  Quant Imaging Med Surg       Date:  2015-10

3.  Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids.

Authors:  Shibdas Banerjee; Richard N Zare; Robert J Tibshirani; Christian A Kunder; Rosalie Nolley; Richard Fan; James D Brooks; Geoffrey A Sonn
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-14       Impact factor: 11.205

4.  [Prostate cancer].

Authors:  T Franiel; N Eckardt; M Waginger; M Horstmann
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

5.  Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.

Authors:  James Kalmuk; Margaret Folaron; Julian Buchinger; Roberto Pili; Mukund Seshadri
Journal:  Oncotarget       Date:  2015-09-15

6.  Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.

Authors:  Arturo Araujo; Leah M Cook; Jeremy S Frieling; Winston Tan; John A Copland; Manish Kohli; Shilpa Gupta; Jasreman Dhillon; Julio Pow-Sang; Conor C Lynch; David Basanta
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

7.  A Comparative Study of 68Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience.

Authors:  Manoj Gupta; Partha S Choudhury; Dibyamohan Hazarika; Sudhir Rawal
Journal:  World J Nucl Med       Date:  2017 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.